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Prostaglandin (PG) E2 is an important inﬂammatory mediator.
We examined pH value and PGE2 concentration in exhaled breath condensate
(EBC) in 22 stable CF adults (11 M) aged 25.6±4.1 years (mean ± SD) with
FEV1 60.7±21.6% pred. and in 12 (4 M) healthy controls aged 27.6±4.2 years
by using ECoScreen condenser. pH was measured without deaeration immediately
after collection (Titan pH-meter with CupFET probe). Samples for PGE2 evaluation
were stored frozen at -80ºC untill they were examined with Luminex technology
(lower detection limit 35 pg/ml). PGE2 was detectable in all CF patients and healthy
controls.
EBC pH was lower in stable CF than in healthy controls (5.50±0.57 vs. 6.09±0.37;
p = 0.0013) whereas EBC PGE2 was higher (6816±4119 vs. 4228±1613 pg/ml;
p = 0.027). In stable CF patients, EBC concentration of PGE2 tended to negative
correlation with EBC pH (r = −0.344; p = 0.122) and was negatively correlated to
FEV1 (r = -0.492; p = 0.02) in contrast to EBC pH, where positive correlation with
FEV1 (r = 0.444; p = 0.038) was found.
We conclude that EBC PGE2 concentration is higher in stable CF patients than in
healthy controls and is negatively correlated to pulmonary function.
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Cystic Fibrosis(CF) infection by gram-neg and -pos bacteria such as Pseudomonas
aeruginosa(PA) and Staphylococcus aureus(SA) causes increase Interleukin (IL)-8
release and chronic inﬂammation. During infection PA undergoes genetic changes
in the Lipid A component of the Lipopolysaccharide(LPS).
We aimed to compare the inﬂammatory response of PA LPS isolates from CF
patients differing in disease severity and SA peptidoglycan(PGN) in NON-CF(HTE)
and CF(CFTE) tracheal epithelial cells.
CFTE and HTE cells were stimulated with LPS(Sigma: PA, PAO1), PGN (SA) or PA
clinical isolates with different Lipid A structure: SE4 (Infant CF), PAK8 (Mild CF),
SE22 (Severe CF), Bronch5 (non-CF, bronchiectasis). IL-8 was measured (ELISA).
LPS isolates (ng/ml) were more potent than Sigma LPS (ug/ml).
Sigma LPS and PA isolates SE22 and PAK8 showed signiﬁcant dose dependent IL-8
release in CFTE (all p< 0.002, ANOVA). SE4 and Bronch5 showed no signiﬁcant
response.
IL-8 release differed signiﬁcantly between both cell lines (100ng/ml): SE22
(p< 0.01) and PAK8 (p< 0.001) induced a higher response in CFTE compared
to HTE.
Comparisons between PA (PaK8, Se22) and SA (all 100ng/ml) showed that PA LPS
produced a higher inﬂammatory response than SA PGN in CFTE (all p< 0.02).
The inﬂammatory response to PA is dependent on strain, cell type and Lipid A
modiﬁcation. To study (patho)physiologically relevant mechanisms of infection an
LPS isolate is preferable to commercial LPS. The association between increased
response to PA over time, genetic modiﬁcation and low inﬂammatory response to
SA may explain the PA dominance over SA in CF airways.
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Pseudomonas aeruginosa is known to be the main pathogen that infects lungs
of cystic ﬁbrosis patients. The innate defense against this pathogen, and many
others, is mediated in part through the recognition of speciﬁc microbial ligands
by Toll-like receptors (TLR), of which there are at least 10 in humans. From in
vivo experiments, using TLR knockout mice, it is assumed that the control of
P. aeruginosa occurs through the recognition of LPS and ﬂagellin by TLR2,4 and 5
respectively. In the present study, we investigated in vitro the role of these same TLR
and ligands, in relation to alveolar macrophages (AM) and respiratory epithelial
cells (EC) activation. Cellular responses to P. aeruginosa were evaluated in terms
of KC, TNF-a, IL-6 and G-CSF secretion, four markers of the innate immune
response. AM and EC from WT and knockout mice for TLR2,4 and TLR4,5 were
stimulated with the wild-type P. aeruginosa or with a mutant devoid of ﬂagellin
expression. The results clearly demonstrate that AM and EC recognize P. aeruginosa
through only two ligand/receptor pairs, i.e. TLR4/LPS and TLR5/ﬂagellin. Either
one is sufﬁcient to trigger cell activation and when both are missing lung AM and
EC are unable to sense the bacterium.
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cPLA2 belonging to a superfamily of enzymes, selectively release arachidonic
acid (AA) from membrane PL. AA metabolites play a role in inﬂammation.
P. aeruginosa is an opportunistic G− bacteria that infects immuno-compromised and
cystic ﬁbroblast patients. This results in high mortality due to its notorious resistance
to antibiotics. We postulated that cPLA2 may play a key role in P. aeruginosa
induced lung inﬂammation.
Our results showed that in A549 epithelial cells, a WT-strain of P. aeruginosa
(PAK) increased cPLA2 phosphorylation which reﬂects its activation, suggesting
that cPLA2 may be involved in P. aeruginosa-induced inﬂammation. Both PAK
and another P. aeruginosa strain, PAO1, induced a time-dependent AA release
from A549 cells. The production of prostaglandin E2 (PGE2), a metabolite of AA,
was increased markedly by PAK which also induced IL8 synthesis. Meanwhile,
PAK induced p38MAPK phosphorylation in a time- and dose-dependent manner.
SB2035803, a speciﬁc inhibitor of p38MAPK, abolished the effect of PAK on both
PGE2 and IL8 synthesis. The expression of cyclooxygenase (COX), which converts
AA into PGE2, was increased after PAK stimulation. Finally, the effects of different
virulence factors isolated from P. aeruginosa were investigated. LPS had no effect
on PGE2 release and IL8 synthesis. Flagellin increased IL8 expression but had no
effect on PGE2 release. The Dﬂic strain, in which the ﬂagellin gene was deleted,
had less effect on IL8 synthesis but had similar effect on PGE2, as compared to
the PAK strain.
Collectively, our results show that cPLA2 is involved in P. aeruginosa-induced
inﬂammation through a process of p38MAPK. However, the virulence factors
involved in cPLA2 activation remains to be identiﬁed.
